Majmudar et al., Circulation. 2013 Apr24 (Epub doi: 10.1161/CIRCULATIONAHA.112.000116) Continue reading…
April 25, 2013
Monocyte-Directed RNAi Targeting CCR2 Improves Infarct Healing in Atherosclerosis-Prone Mice
January 30, 2013
Complete Study Results from our ALN-VSP Phase I Trial and Extension Study Published in Cancer Discovery
We have published complete study results from our Phase I clinical trial with ALN-VSP, an RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. Results from the study – the most comprehensive study of a systemically administered RNAi therapeutic to date – demonstrated proof of RNAi activity in man and evidence of anti-tumor activity, in addition to highlighting the safety and tolerability of multiple doses of ALN-VSP.
Read the abstract in Cancer DiscoveryDecember 8, 2012
An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe-/- mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia
November 21, 2012
An immobilized and reusable Cu(i) catalyst for metal ion-free conjugation of ligands to fully deprotected oligonucleotides through click reaction.
November 21, 2012
Evaluation of exogenous siRNA addition as a metabolic engineering tool for modifying biopharmaceuticals
October 3, 2012
Silencing of Lipid Metabolism Genes through IRE1α-Mediated mRNA Decay Lowers Plasma Lipids in Mice
September 1, 2012
Solid-phase chemical synthesis of 5′-triphosphate DNA, RNA, and chemically modified oligonucleotides.
July 10, 2012
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo
June 22, 2012
